Go Symbol Lookup
Loading...

Cramer’s One-on-One With Regeneron CEO

 Text Size  
Published: Tuesday, 10 Jan 2012 | 7:25 PM ET
By:

Producer

Cramer's Speculative Biotech Play: Regeneron
Len Schleifer, Regeneron Pharmaceuticals CEO, discusses smart biotech investing and growth prospects in the company's pipeline, with Mad Money's Jim Cramer.

On Tuesday, Cramer spoke with Dr. Leonard Schleifer, president and CEO of Regeneron Pharmaceuticals .

Based in Tarrytown, N.Y., Regeneron is a biopharmaceutical company that discovers, develops and commercializes pharmaceutical products for the treatment of serious medical conditions, including and especially in the area of eye care.

Cramer has long been behind the company’s stock. He first recommended REGN when it was trading at around $5 a share in spring 2005. Those who bought the stock at those levels and have held on have seen a 1,425 percent gain. But does this stock have even more room to run? Find out by watching video of Cramer’s full conversation with Dr. Leonard Schleifer.









Call Cramer: 1-800-743-CNBC

Questions for Cramer? madmoney@cnbc.com

Questions, comments, suggestions for the Mad Money website? madcap@cnbc.com

 Print
Dr. Leonard Schleifer, president and CEO of Regeneron, appears on “Mad Money.”
  Price   Change %Change
REGN ---

   
Comments

 

More Comments

 
 

Add Comments

 

Your Comments (Up to 1100 characters):

Remaining characters

Your comments have not been posted yet.

Please review your submission to make sure you are comfortable with your entry.

Your Comments:


                
            
            
        

Featured

Contact Mad Money

  • Showtimes

    Monday - Friday 6p | 11p ET
  • Cramer is host of CNBC's "Mad Money," and co-anchor of the 9 a.m. ET hour of CNBC's "Squawk on the Street."

Mad Money Features

  • Grab the latest CNBC gear from the NBCUniversal Store!

  • Get a behind-the-scenes look at how Cramer formulates his investment advice. "Inside the Madness" is a column, which features e-mails and more with Cramer and his researcher Nicole Urken.

  • You’ve always wanted to hit the “Hallelujah!” button. Here’s your chance.